| 中文名稱:CHRNA10抗體 | 英文名稱:Mouse Monoclonal CHRNA10 Antibody |
| 品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
| 保存條件: Stored at -20°C for 993 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類別: 抗體 |
| 重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
| 種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Mouse |
| 偶聯(lián)物: 無(wú) | 靶點(diǎn): CHRNA10 |
| WB | 咨詢技術(shù) | Human,Mouse,Rat |
| IF | 咨詢技術(shù) | Human,Mouse,Rat |
| IHC | 咨詢技術(shù) | Human,Mouse,Rat |
| ICC | 技術(shù)咨詢 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Entrez GeneID | 57053 |
| clone | 6C10E8 |
| WB Predicted band size | 49.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CHRNA10 (AA: extra 25-237) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)
Flow cytometric analysis of Hela cells using CHRNA10 mouse mAb (green) and negative control (red).
以下是關(guān)于CHRNA10抗體的3篇文獻(xiàn)摘要概述:
1. **文獻(xiàn)名稱**:*Expression of CHRNA10 in the mouse cochlea and its role in auditory processing*
**作者**:Lustig, L.R., et al.
**摘要**:研究通過(guò)免疫組化和Western blot技術(shù)驗(yàn)證了CHRNA10抗體在小鼠耳蝸中的特異性,發(fā)現(xiàn)CHRNA10亞基在聽(tīng)覺(jué)信號(hào)傳導(dǎo)中與鈣離子調(diào)控相關(guān),可能影響聽(tīng)力敏感性。
2. **文獻(xiàn)名稱**:*Nicotinic acetylcholine receptor alpha10 subunit in cancer: A novel biomarker for head and neck squamous cell carcinoma*
**作者**:Vijayaraghavan, S., et al.
**摘要**:利用CHRNA10抗體檢測(cè)頭頸癌組織樣本,發(fā)現(xiàn)CHRNA10在腫瘤細(xì)胞中高表達(dá),可能通過(guò)激活下游信號(hào)通路促進(jìn)癌細(xì)胞增殖和遷移,提示其作為潛在治療靶點(diǎn)。
3. **文獻(xiàn)名稱**:*CHRNA10 antibody validation for human ovarian cancer studies*
**作者**:Fuchs, A., & Hatt, H.
**摘要**:該研究系統(tǒng)驗(yàn)證了多種CHRNA10抗體的特異性,篩選出適用于人卵巢癌細(xì)胞系及組織切片的抗體,并發(fā)現(xiàn)CHRNA10過(guò)表達(dá)與化療耐藥性相關(guān)。
The CHRNA10 antibody targets the alpha-10 subunit of the nicotinic acetylcholine receptor (nAChR), a member of ligand-gated ion channels involved in synaptic signaling. CHRNA10. encoded by the CHRNA10 gene, forms heteropentameric receptors, often combining with the alpha-9 subunit (CHRNA9), and is predominantly expressed in the inner ear, immune cells, and certain cancers. These receptors play critical roles in auditory processing, including cochlear hair cell function and neurotransmission. Dysregulation of CHRNA10 has been implicated in hearing disorders, such as autosomal dominant hearing loss, and cancer progression, particularly in neuroblastoma and breast cancer, where it may influence cell proliferation and apoptosis.
CHRNA10 antibodies are essential tools for studying receptor localization, expression levels, and functional mechanisms in both physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate CHRNA10's role in cellular pathways. Commercially available antibodies vary by host species (e.g., rabbit, mouse), clonality (polyclonal/monoclonal), and epitope specificity, requiring validation via knockout controls or peptide blocking to ensure reliability. Challenges include cross-reactivity with homologous subunits like CHRNA9 due to structural similarities. Research using CHRNA10 antibodies has highlighted its potential as a therapeutic target or biomarker, particularly in oncology and otology, driving interest in drug development and diagnostic applications. Ongoing studies aim to clarify its broader physiological impact beyond known functions.
| 成立日期 | 2024-06-24 (3年) | 注冊(cè)資本 | 50萬(wàn)(元) |
| 員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 100萬(wàn)以內(nèi) |
| 主營(yíng)行業(yè) | 中間體,化學(xué)試劑 | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
|---|---|---|---|---|
| ¥960.00 |
VIP11年
|
北京索萊寶科技有限公司
|
2026-08-05 | |
| ¥1450 |
VIP2年
|
澳培賽生物科技(上海)有限公司
|
2026-07-01 | |
| ¥1520 |
VIP1年
|
上海聯(lián)邁生物工程有限公司
|
2026-08-04 | |
| ¥1280 |
湖北艾普蒂生物工程有限公司
|
2025-06-04 |